Novo Nordisk's Ozempic is seen in this illustration photo taken in a pharmacy in Krakow, Poland, on Dec. 7. Photo: Jakub Porzycki/NurPhoto via Getty Images
OG Closer readers may rememberCourtenay Brown's story in May 2021 on how there's an exchange-traded fund (ETF) for nearly everything these days.
State of play: Well, now there's an ETF for the weight-loss drug boom.
Roundhill Investments this week debuted an ETF "focused exclusively on the rapidly growing sector of GLP-1 receptor agonists and other weight management drugs."
Zoom in: 20% is Novo Nordisk (maker of Ozempic and Wegovy), while 20% is Eli Lilly (maker of Mounjaro and Zepbound).
Other parts of the portfolio include Amgen and Viking Therapeutics.
